The rate of relapse among patients with TP53-mutated myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) was similar among those who underwent allogeneic hematopoietic stem cell transplant ...

The rare disease Fanconi anemia is an inherited bone marrow disorder linked to birth defects that leads to failure of bone marrow, the spongy material inside the bones where stem cells develop.

Researchers sought to determine whether combining enasidenib with venetoclax would be effective in patients with IDH2-mutated ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. So, in terms of preventing MDS, that's a ...

Mavenclad and Venclexta combination achieved a 96% ORR in newly diagnosed AML and high-risk MDS patients, with high CR rates in MRD-negative individuals. The study reported a 2-year OS rate of 100% ...

Findings showed the hazard ratio for OS compared with busulfan was 0.67 in all randomized patients. The Food and Drug Administration (FDA) has approved Grafapex ™ (treosulfan) for injection with ...

The FDA approved treosulfan (Grafapex) with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in patients ages 1 year and older with acute myeloid leukemia ...

Tuspetinib selected for a prestigious national clinical research program for ability to target broad spectrum of AML and MDS populations Trials to test tuspetinib in targeted drug combinations for ...

– Observed 79% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete response (CR)/marrow complete response (mCR) rate of 64% – – Observed 27% ...

Electronic databases searched through October 2008 identified 3,794 articles for initial screening. Eligibility included solid tumor or lymphoma patients randomly assigned to chemotherapy with or ...

SAN DIEGO and TORONTO, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly ...